Print
Brian S. Nightengale, Ph.D.
Corporate Scientific Officer and Executive Vice President
XCENDA, Palm Harbor, Florida
Dr. Nightengale has over 15 years of experience in health economics and outcomes research, pharmaceutical utilization, decision support and quality improvement research. In addition, Dr. Nightengale has extensive experience in pharmaceutical marketing, strategy and health policy analysis. He has worked with numerous health plans, provider organizations and state agencies in designing and implementing pharmaceutical utilization and quality improvement projects. He has participated in the design and development of over 50 software-based economic models and over 100 formulary dossiers for use in managed care and institutional decision-making.
Dr. Nightengale earned his Bachelor of Science degree from the University of Oklahoma College of Pharmacy in 1990, and subsequently his Ph.D. from the University of South Carolina. He returned to OUHSC College of Pharmacy as an Assistant Professor of Pharmacy Administration from 1994-1996.
As Xcenda's Corporate Scientific Officer, Dr. Nightengale is primarily responsible for ensuring that Xcenda's intellectual property is state of the art and that Xcenda's consulting professionals are equipped to provide the most scientifically sound and methodologically rigorous services in the industry. As Executive Vice President, Dr. Nightengale leads the Biopharma Strategies Practice Area and works with multiple biopharmaceutical research and manufacturing firms in developing product commercialization strategies and research program consultation across all phases of the development process. Dr. Nightengale provides expertise and insights related to the business development, sales and marketing activities of Xcenda and, along with other members of the senior management team, provides direction and management of the firm.
Xcenda is a strategic consulting firm with offices in Palm Harbor, Florida; Princeton, New Jersey; and Salt Lake City, Utah. Dr. Nightengale joined Xcenda in 1996 as a partner in the firm.
About the lecture
"Xcenda is a strategic consulting firm with offices in Palm Harbor, Florida; Princeton, New Jersey; and Salt Lake City, Utah. Dr. Nightengale joined Xcenda in 1996 as a partner in the firm."
Both private and public health care payers and providers are requiring more and more evidence of a product or new technology’s value before advocating its use within their organization or population. While the broad definition of “value” is consistently described, the metrics upon which value are measured often differ based on the perspective of the audience or stakeholder. In an increasing number of cases, the evidentiary requirements of a product’s value go well beyond the safety and efficacy data provided by clinical trials. As consumers and payers yield more influence in product use and coverage decisions, the data coming from naturalistic observational studies, disease registries, and retrospective analyses will increasingly be valued. As a result, private and public funding entities are investing more resources for these types of studies. These trends provide significant opportunities for researchers, practitioners, and provider organizations to enhance and grow their research programs and funding.
During his presentation, Dr. Nightengale will draw from his experiences in building and growing a successful research organization to provide insights and tips on how best to capitalize on these evidentiary trends. Specifically, Dr. Nightengale will address the following questions:
- Why should I focus on pharmacoepidemiologic/ outcomes data?
- How can I best leverage my organizations data to meet these growing market needs?
- What can I do to enhance funding opportunities while generating credible and impactful results?
Dr. Nightengale will discuss, in an open dialog format, five key strategies to improve funding and generate credible and impactful results for publication. These strategies are intended to benefit clinicians, clinical researchers, basic science researchers, pharmaco-economists, and organizational administrators. Likewise, students will benefit from the discussion if they are contemplating a career in the pharmaceutical industry, consulting services/contract research organization (CRO) industry, academia, managed care, hospital pharmacy, or long-term care.
Quoted from the 2007-2008 Linda H. and Calvin J. Anthony Distinguished Entrepreneur in Pharmacy Lecture Series Announcement Brochure